Condition: Urinary Bladder Neoplasms

Study Type: Observational

Clinical Trials Identifier NCT 8-digits: NCT05742867

Sponsor: Bristol-Myers Squibb

Phase:

Eligibility:

• Age: minimum 18 Years maximum N/A
• Gender: All

Inclusion Criteria:

• Must reside in Japan and able to speak/read Japanese for the interview/survey
• Must have a clinical diagnosis of Muscle-invasive bladder cancer (MIBC):
• ypT2-ypT4a or ypN+ MIBC, with prior neoadjuvant cisplatin chemotherapy and underwent radical cystectomy
• pT3-pT4a or pN+ MIBC, without prior neoadjuvant cisplatin chemotherapy and underwent radical cystectomy
• Must not have received any treatment related to MIBC after radical cystectomy

Exclusion Criteria:

• Determined by the physician as being unsuitable for the study (e.g. having any clinically significant psychiatric disorder, cognitive impairment, or having difficulty with communicating in Japanese)
• Confirmed diagnosis of other primary cancers at the time of obtaining consent
• Current participation in a MIBC clinical trial

View trial on ClinicalTrials.gov